Unlock instant, AI-driven research and patent intelligence for your innovation.

Embolic agent as well as preparation method thereof

A technology of embolic agents and liposomes, applied in the field of pharmaceuticals for the treatment of liver cancer, can solve the problems of being easily taken out of the embolism area, difficult to find/treat, and no synergistic comprehensive application, etc., to achieve good embolism stability and biological safety. Effect

Active Publication Date: 2014-12-17
SOUTHEAST UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The current embolic agents have obvious embolization effects on large tumors with rich blood supply in clinical treatment, but the disease progresses soon after the tumor is controlled in a short period of time, mainly because: ① Tumor vascular embolization is not complete (large liver cancer), and it is difficult to find / Treat potential lesions (microscopic lesions in the liver)
The thinnest lipiodol can only block the terminal blood vessels of 5-10 microns, and it can do nothing for the finer new blood vessels, while the gelatin sponge particles and PVA (polyvinyl alcohol) microspheres are generally only used to strengthen the embolization of the middle blood vessels. Embolization of small blood vessels; ②Single treatment method
Existing embolic agents can only be used for one embolization treatment, and currently there is no ability to synergistically use chemotherapy, radiotherapy, hyperthermia or biological treatment at the same time; Easily carried out of the embolized area

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Embolic agent as well as preparation method thereof
  • Embolic agent as well as preparation method thereof
  • Embolic agent as well as preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Embolic agent of the present invention is made by following method:

[0026] (1) Synthetic package has 131 Liposomes of I-iodol and magnetic nanoparticles;

[0027] (1a) the oil-soluble F e3 o 4 Nanoparticles dispersed in 131 In I-iodol, a mixed solution is formed;

[0028] (1b) Add the mixed solution described in step (1a) as an oil phase to the aqueous phase containing aminated polyethylene glycol (PEG) monostearate, and stir for 30 minutes to form a colostrum cloudy solution;

[0029] (1c) Ultrasonic the colostrum turbid liquid described in step (1b) for 5 minutes with an ultrasonic breaker, and the colostrum turbid liquid is converted into a stable oil-in-water nanoemulsion, finally obtaining a suitable size, good uniformity, good stability, Transparent and clear magnetic with high biocompatibility 131 I-iodol nanoemulsion; the magnetic 131 I-iodol nanoemulsion is coated with magnetic nanoparticles and 131 The liposome of 1-iodol, its particle diameter is 10...

Embodiment 2

[0036] Embolic agent of the present invention is made by following method:

[0037] (1) Synthetic package has 131 Liposomes of I-iodol and magnetic nanoparticles;

[0038] (1a) the oil-soluble γ -Fe 2 o 3 The nanoparticles are dispersed in the iodine-131 carburetion injection to form a mixed solution;

[0039] (1b) adding the mixed solution described in step (1a) as an oil phase into an aqueous phase containing carboxylated polyethylene glycol (PEG) monostearate, stirring for 60 min to form a colostrum turbid solution;

[0040] (1c) Ultrasonic the colostrum turbid liquid described in step (1b) for 30 minutes with an ultrasonic breaker, and the colostrum turbid liquid is converted into a stable oil-in-water nanoemulsion, finally obtaining a suitable size, good uniformity, good stability, Transparent and clear magnetic with high biocompatibility 131 I-iodol nanoemulsion; the magnetic 131 I-iodol nanoemulsion is coated with magnetic nanoparticles and 131 The liposome of 1...

Embodiment 3

[0047] The average survival rate of 30 patients with liver cancer (not receiving any treatment) was selected as the control group. 125 The survival rate of patients with liver cancer after interventional therapy with I-iodol embolism was used as the control group 2. 131 I-iodine's metuximab injection carries out the survival rate of patients with liver cancer after radioimmunotherapy as a control group 3, and the survival rate of patients with liver cancer after the embolization agent (embodiment 1) interventional therapy provided by the present invention is used as an experimental group .

[0048] Efficacy comparison: experimental data shows that the survival rate of liver cancer patients (liver cancer patients who survived to 24 months) in the control group is less than 10%. 131 The survival rate of patients with liver cancer after I-iodine metuximab treatment (liver cancer patients who survived to 24 months) was less than 50%, using 125 The survival rate of liver cancer p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
Login to View More

Abstract

The invention discloses an embolic agent, and further discloses a preparation method of the embolic agent, finally discloses a use method of the embolic agent. The embolic agent comprises liposomes in which <131>I-lipiodol and magnetic nanoparticles are wrapped, the magnetic nanoparticles are dispersed in the <131>I-lipiodol, and anticancer drugs are connected on the outer surface of the liposomes. According to the invention, embolotherapy, radiotherapy, thermotherapy and immunotherapy are combined effectively and various parts give play to synergies, simultaneously, the embolic agent has good embolism stability and biological safety, furthermore, nanomaterials are introduced into the interventional embolotherapy of tumors, thereby being beneficial to researches and application of the cancer comprehensive treatment.

Description

technical field [0001] The present invention relates to a medicament for treating liver cancer, in particular to a embolic agent, and also relates to a preparation method of the embolic agent. Background technique [0002] Hepatocellular carcinoma (Hepatocellular Carcinoma, HCC) is one of the most common malignant tumors in my country, with rapid progression and poor prognosis after onset. Most liver cancer patients are in the middle and late stage when they are discovered, multiple metastatic tumors are common in the liver area, and there is no opportunity for radical surgery. Commonly used non-surgical treatment methods include: transcatheter arterial chemoembolization (TACE), radiation therapy, local ablation therapy and biological immunotherapy. Among them, TACE is currently the most widely used method with the best curative effect in the non-surgical treatment of liver cancer. The theoretical basis of TACE treatment is to use heterogeneous substances incompatible with...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/00A61K51/00A61K41/00A61K39/395A61P35/00A61K101/02
Inventor 孙剑飞邱爽葛乃建刘璇藤皋军顾宁
Owner SOUTHEAST UNIV